# EDGAR Filing Document

**Accession Number:** 0001673772
**File Stem:** 0001193125-26-112753
**Filing Date:** 2026-3
**Character Count:** 3444
**Document Hash:** e2603cf0b74b7a626eeacf540986bdfe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-112753.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001193125-26-112753

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**EFFECTIVENESS DATE**: 20260318

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RAPT Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001673772
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473313701
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38997
- **FILM NUMBER:** 26766077

**BUSINESS ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 489-9000

**MAIL ADDRESS:**
- **STREET 1:** 561 ECCLES AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLX Bio, Inc.
- **DATE OF NAME CHANGE:** 20160504

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File Number: 001-38997** 

## RAPT Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

**561 Eccles Avenue** 

**South San Francisco, California 94080** 

**Tel: (650) 489-9000** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common stock, par value $0.0001 per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: 1\*

\* Pursuant to an Agreement and Plan of Merger, dated as of January 19, 2026, by and among RAPT Therapeutics, Inc., a Delaware corporation ("<u>Company</u>"), GlaxoSmithKline LLC, a Delaware limited liability company ("<u>Parent</u>"), Redrose Acquisition Co., a Delaware corporation ("<u>Merger Sub</u>"), and solely for the purposes set forth therein, GSK plc, a public limited company organized under the laws of England and Wales, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent. 

------

Pursuant to the requirements of the Securities Exchange Act of 1934, RAPT Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: March 18, 2026

---

| | |
|:---|:---|
| RAPT THERAPEUTICS, INC. | RAPT THERAPEUTICS, INC. |
| By: | /s/ Justin Huang |
| Name: | Justin Huang |
| Title: | President and Secretary |

---